Related Experiment Videos
[Pyridoxine-dependent epilepsy in an infant]
W M van Waarde1, R F Tummers, A N Bosschaart
1Medisch Spectrum Twente, Enschede.
Nederlands Tijdschrift Voor Geneeskunde
|August 19, 1995
Summary
Pyridoxine-dependent seizures, a rare genetic disorder, can be successfully treated with pyridoxine. Early diagnosis is crucial for a favorable prognosis in infants with this condition.
Area of Science:
- Biochemistry
- Genetics
- Pediatric Neurology
Background:
- Pyridoxine-dependent seizures (PDS) are an uncommon inherited metabolic disorder.
- The condition presents with a variable clinical picture, often mimicking other neonatal neurological conditions.
- Autosomal-recessive inheritance patterns are characteristic of PDS.
Observation:
- A newborn infant experienced intractable seizures despite conventional anticonvulsive therapies.
- The infant's seizures resolved completely following administration of pyridoxine (Vitamin B6).
- This case highlights a potential diagnostic challenge where initial responses to standard treatments can be misleading.
Findings:
- Pyridoxine administration is a highly effective treatment for pyridoxine-dependent seizures.
- Early identification of PDS is critical for optimal patient outcomes.
- Delayed diagnosis can occur due to confusion with perinatal asphyxia and transient responses to standard anticonvulsants.
Implications:
- This case underscores the importance of considering PDS in neonates with unexplained seizures.
- Prompt diagnosis and targeted pyridoxine therapy can prevent long-term neurological damage.
- Increased awareness among clinicians can improve the management of this rare genetic epilepsy.